Table 1.
Characteristics of U.S. adults eligible for SPRINT overall and by antihypertensive medication status using NHANES 1999–2006.
| Group | Overall (n=18.1 million) | Taking Antihypertensive Medication (n=7.4 million) | Not Taking Antihypertensive Medication (n=10.7 million) | SPRINT* (n=9,361) |
|---|---|---|---|---|
| Age, mean (SE), years | 68.6 (0.26) | 68.8 (0.32) | 68.5 (0.37) | 67.9 (9.4) |
| Age group, % | ||||
| < 75 years | 68.0 | 68.1 | 67.7 | 71.8 |
| ≥ 75 years | 32.0 | 31.9 | 32.3 | 28.2 |
| Male sex, % | 53.8 | 46.1 | 53.8 | 64.4 |
| Race/ethnicity, % | ||||
| Non-Hispanic White | 83.2 | 82.9 | 83.4 | 57.7 |
| Non-Hispanic Black | 7.4 | 9.3 | 6.0 | 29.9 |
| Mexican American | 3.0 | 2.2 | 3.5 | NA |
| Other | 6.5 | 5.6 | 7.1 | 1.88 |
| Current smoker, % | 17.6 | 10.3 | 17.6 | 13.2 |
| Body mass index, mean (SE) | 28.1 (0.13) | 29.1 (0.21) | 27.5 (0.17) | 29.9 (5.7) |
| Obese, % | 31.0 | 37.2 | 26.7 | NA |
| eGFR 20 to 59 ml/min/1.73 m2, % | 23.0 | 26.1 | 20.2 | 28.3 |
| Framingham risk score groups, % | ||||
| < 5% | 0.2 | 0.0 | 0.39 | NA |
| 5.0–7.4% | 0.8 | 0.8 | 0.7 | NA |
| 7.5–9.9% | 1.6 | 1.5 | 1.6 | NA |
| 10 – 14.9% | 6.3 | 5.9 | 6.6 | NA |
| ≥ 15% | 91.1 | 91.9 | 90.6 | 61.3 |
| History of CHD, % | 12.1 | 16.9 | 8.7 | 16.7 |
| Systolic blood pressure, mmHg, % | ||||
| ≤132 | 9.9 | 7.3 | 11.7 | 33.5 |
| 133 – 144 | 40.7 | 43.6 | 38.8 | 32.5 |
| ≥145 | 49.4 | 49.1 | 49.5 | 34.0 |
| Education, % | ||||
| Less than high school | 26.0 | 23.1 | 28.0 | NA |
| High school only | 29.5 | 27.8 | 30.7 | NA |
| More than high school | 25.2 | 27.7 | 23.4 | NA |
| Completed college | 19.3 | 21.3 | 17.9 | NA |
| No insurance, % | 11.0 | 7.4 | 13.5 | NA |
Numbers in table are expressed as mean (Standard error [SE]) or percentages. Percentages are based on weighted data. CVD - cardiovascular disease, eGFR - estimated glomerular filtration rate, SPRINT - Systolic Blood Pressure Intervention Trial, CHD=coronary heart disease, NHANES= National Health and Nutrition Examination Survey, NA=not applicable.
Obesity defined as body mass index ≥ 30.0 kg/m2. Framingham risk score was calculate using the using the equation for general clinical practice.13 Use of antihypertensive medication was defined by self-report and report of taking one or more classes of antihypertensive medication identified through the pill bottle review.
Baseline characteristics from SPRINT are shown for comparisons (mean and standard deviation are shown for age and body mass index).